Clinical Research Fellows
To promote clinical research and support future clinical research leaders SRP Diabetes supports Clinical Research Fellows through the program “Clinical Research Position Grants in Diabetology”. Through an open call four applicants were awarded grants in December 2013; Ingrid Dahlman, Lisa Juntti-Berggren, Mikael Rydén and Sergiu-Bogdan Catrina. The intent of the grants are to enable the recipients (medical doctors with specialist certificate) to conduct research within diabetology on a half-time basis, while developing the clinical competence. The awarded grant is to cover a half-time salary as clinician, i.e. 850 000 SEK per year for 2 years.
Sergiu-Bogdan Catrina completed his MD in 1991 at the University of Medicine and Pharmacy “Carol Davila”, Bucharest Romania. He defended his first PhD in 2001 at the same university on the purification of a new active substance in pineal gland and his second PhD in 2005 at Karolinska Institute on the regulation of angiogenesis in diabetes and tumors in the laboratory of Professor Kerstin Brismar. Dr. Catrina is a Consultant in Endocrinology since 2000 and became an Associate Professor in Endocrinology at Karolinska Institute at 2012. He is currently working at the Department of Endocrinology, Karolinska University Hospital in Solna. Dr. Catrinas research is focused on the pathogenic mechanisms contributing to the development of chronic complications in diabetes. His research group has recently demonstrated that hyperglycemia modulates cellular mechanisms that are essential for angiogenesis and cell differentiation such as the HIF-mediated reaction to hypoxia. They are further exploring these signalling systems and their interaction both in vivo and in vitro to be able to design new therapeutic strategies and define biomarkers for chronic diabetes complications.
Ingrid Dahlman completed her MD at the Karolinska Institute in 1996, and in 1999 defended her thesis on genetic regulation of experimental autoimmne neuroinflammatory diseases in the laboratory of Professor Tomas Olsson. During her thesis work Ingrid became interested in human genetics and in 2001 she did a post doc in Professor John A Todd’s laboratory in Cambridge working on genetics of type 1 diabetes. Ingrid is employed as a Consultant in Endocronology and Diabetes at Ersta hospital and affiliated with the Lipid laboratory at the Department of Medicine, Huddinge. Ingrid became Associate professor in 2005, and Consultant in Endocrinology in 2007. In 2010 she attained a part-time senior research position financed by the Swedish Research council. Ingrid’s current research is focused on the role of human adipose tissue in development of obesity associated insulin resistance. More precisely, she applies global transcriptomic analyses and other pangenomic approaches to identify new mediators and regulators of insulin resistance in human fat cells.
Lisa Juntti-Berggren completed her MD at the University of Uppsala and in 1992 she defended her thesis ”Elemental content, intracellular pH and cytoplasmic Ca2+ in insulin-secreting cells under physiological conditions and diabetes” at the Dept of Medical Cell Biology, Uppsala University. Thereafter she did a residency at the Dept of Endocrinology, Karolinska University Hospital where she is now a senior consultant. She is specialized in Internal Medicine and Endocrinology and is Associate Professor in Endocrinology since 1997. In 2009 she got a 50% research position in Experimental Medicine from the Swedish Research Council. After moving to Stockholm she continued her research at The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, which is based on the findings during her thesis work that serum from patients with type-1 diabetes increases voltage-gated Ca2+-channel activity and the subsequent increase in cytoplasmic free Ca2+ concentration, [Ca2+]i, is associated with apoptosis. She has identified the serum factor to be apolipoprotein CIII (apoCIII) and the focus is on the in vivo effects of apoCIII and to identify the mechanisms whereby apoCIII affects the β-cell. Not only is apoCIII of interest in type-1 diabetes it has also been shown to be increased in patients with type-2 diabetes and it is known that insulin resistance up-regulates the apoCIII gene. The utmost aim of her project is to identify targets and develop tools to safely reduce apoCIII primarily in individuals at risk for diabetes and/or cardiovascular disorders.
Mikael Rydén gained his M.D. at the Karolinska Institute in 1996 and defended his PhD in molecular neurobiology at the department of medical biochemistry and biophysics the following year. After a post-doctoral stay at the department of Medicine at Huddinge University Hospital, he became associate professor in 2002. In his clinical training he became a board certified specialist in 2005 and obtained a combined appointment as senior consultant/senior lecturer in 2010. The same year he was also appointed head of the Center for Clinical Metabolic Research in Diabetes within the Strategic Research program in Diabetes at Karolinska Institutet. In July 2013, he was appointed professor of Clinical and Experimental Fat Tissue Research at the Department of Medicine, Karolinska, Huddinge. Prof Rydén’s research revolves around white adipose tissue, the most plastic organ in the human body. While it has previously been regarded primarily as an energy-storing tissue, it is now well-established that it plays a central role in the development of insulin resistance, dyslipidemia and atherosclerosis in clinical conditions such as overweight/obesity, type 2 diabetes, familial combined hyperlipidaemia, chronic renal failure, cancer, cachexia and polycystic ovary syndrome. Prof Rydén's research focuses on the patophysiological disturbances that promote a pernicious adipose tissue phenotype and combines cell and molecular biotechnologies in various cell culture systems with clinical studies.